{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:20:00Z","timestamp":1791814800409,"version":"4.3.4"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2016,1,28]],"date-time":"2016-01-28T00:00:00Z","timestamp":1453939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Centre","doi-asserted-by":"publisher","award":["DEC-2012\/05\/E\/NZ5\/00590"],"award-info":[{"award-number":["DEC-2012\/05\/E\/NZ5\/00590"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The aim of this study was to assess the net clinical and prognostic effects of intravenous (i.v.) iron therapy in patients with systolic heart failure (HF) and iron deficiency (ID).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We performed an aggregate data meta-analysis (random effects model) of randomized controlled trials that evaluated the effects of i.v. iron therapy in iron-deficient patients with systolic HF. We searched electronic databases up to September 2014. We identified five trials which fulfilled the inclusion criteria (509 patients received i.v. iron therapy in comparison with 342 controls). Intravenous iron therapy has been shown to reduce the risk of the combined endpoint of all-cause death or cardiovascular hospitalization [odds ratio (OR) 0.44, 95% confidence interval (CI) 0.30\u20130.64, P &amp;lt; 0.0001], and the combined endpoint of cardiovascular death or hospitalization for worsening HF (OR 0.39, 95% CI 0.24\u20130.63, P = 0.0001). Intravenous iron therapy resulted in a reduction in NYHA class (data are reported as a mean net effect with 95% CIs for all continuous variables) (\u22120.54 class, 95% CI \u22120.87 to \u22120.21, P = 0.001); an increase in 6-min walking test distance (+31\u2009m, 95% CI 18\u201343, P &amp;lt; 0.0001); and an improvement in quality of life [Kansas City Cardiomyopathy Questionnaire (KCCQ) score +5.5 points, 95% CI 2.8\u20138.3, P &amp;lt; 0.0001; European Quality of Life\u20135 Dimensions (EQ-5D) score +4.1 points, 95% CI 0.8\u20137.3, P = 0.01; Minnesota Living With Heart Failure Questionnaire (MLHFQ) score \u221219 points, 95% CI:\u201323 to \u221216, P &amp;lt; 0.0001; and Patient Global Assessment (PGA) +0.70 points, 95% CI 0.31\u20131.09, P = 0004].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The evidence indicates that i.v. iron therapy in iron-deficient patients with systolic HF improves outcomes, exercise capacity, and quality of life, and alleviates HF symptoms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.473","type":"journal-article","created":{"date-parts":[[2016,1,28]],"date-time":"2016-01-28T23:38:08Z","timestamp":1454024288000},"page":"786-795","source":"Crossref","is-referenced-by-count":301,"title":["Effects of Intravenous Iron Therapy in Iron-Deficient Patients with Systolic Heart Failure: A Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1093","volume":"18","author":[{"given":"Ewa A.","family":"Jankowska","sequence":"first","affiliation":[{"name":"Laboratory for Applied Research on Cardiovascular System, Department of Heart Diseases, Wroclaw Medical University , Wroclaw ,","place":["Poland"]},{"name":"Cardiology Department, Centre for Heart Diseases, Military Hospital , Wroclaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Tkaczyszyn","sequence":"additional","affiliation":[{"name":"Laboratory for Applied Research on Cardiovascular System, Department of Heart Diseases, Wroclaw Medical University , Wroclaw ,","place":["Poland"]},{"name":"Cardiology Department, Centre for Heart Diseases, Military Hospital , Wroclaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Suchocki","sequence":"additional","affiliation":[{"name":"Biostatistics Group, Department of Genetics, Wroclaw University of Environmental and Life Sciences , Wroclaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Drozd","sequence":"additional","affiliation":[{"name":"Laboratory for Applied Research on Cardiovascular System, Department of Heart Diseases, Wroclaw Medical University , Wroclaw ,","place":["Poland"]},{"name":"Cardiology Department, Centre for Heart Diseases, Military Hospital , Wroclaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"von Haehling","sequence":"additional","affiliation":[{"name":"Division of Innovative Clinical Trials, Department of Cardiology & Pulmonology, University Medicine G\u00f6ttingen (UMG) , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Doehner","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Virchow Klinikum, Charite \u2013 Universit\u00e4tsmedizin , Berlin ,","place":["Germany"]},{"name":"Center for Stroke Research Berlin, Charite \u2013 Universit\u00e4tsmedizin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldemar","family":"Banasiak","sequence":"additional","affiliation":[{"name":"Cardiology Department, Centre for Heart Diseases, Military Hospital , Wroclaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"Heart Failure Unit, Department of Cardiology, Athens University Hospital Attikon , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[{"name":"Division of Innovative Clinical Trials, Department of Cardiology & Pulmonology, University Medicine G\u00f6ttingen (UMG) , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Cardiology Department, Centre for Heart Diseases, Military Hospital , Wroclaw ,","place":["Poland"]},{"name":"Department of Heart Diseases, Wroclaw Medical University , Wroclaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,1,28]]},"reference":[{"key":"2026011721151587800_ejhf473-bib-0001","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ahj.2013.01.017","article-title":"Iron deficiency in chronic heart failure: an international pooled analysis","volume":"165","author":"Klip","year":"2013","journal-title":"Am Heart J"},{"key":"2026011721151587800_ejhf473-bib-0002","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/j.jacc.2006.08.034","article-title":"Etiology of anemia in patients with advanced heart failure","volume":"48","author":"Nanas","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026011721151587800_ejhf473-bib-0003","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/eurheartj\/ehs224","article-title":"Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives","volume":"34","author":"Jankowska","year":"2013","journal-title":"Eur Heart J"},{"key":"2026011721151587800_ejhf473-bib-0004","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/eurheartj\/ehq158","article-title":"Iron deficiency: an ominous sign in patients with systolic chronic heart failure","volume":"31","author":"Jankowska","year":"2010","journal-title":"Eur Heart J"},{"key":"2026011721151587800_ejhf473-bib-0005","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.cardfail.2011.08.003","article-title":"Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure","volume":"17","author":"Jankowska","year":"2011","journal-title":"J Card Fail"},{"key":"2026011721151587800_ejhf473-bib-0006","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijcard.2014.03.169","article-title":"Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study","volume":"174","author":"Enjuanes","year":"2014","journal-title":"Int J Cardiol"},{"key":"2026011721151587800_ejhf473-bib-0007","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nrcardio.2011.77","article-title":"Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches","volume":"8","author":"van Veldhuisen","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"2026011721151587800_ejhf473-bib-0008","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/ejhf.161","article-title":"Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis","volume":"16","author":"Yeo","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026011721151587800_ejhf473-bib-0009","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/eurheartj\/ehs377","article-title":"Iron status in patients with chronic heart failure","volume":"34","author":"Jankowska","year":"2013","journal-title":"Eur Heart J"},{"key":"2026011721151587800_ejhf473-bib-0010","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/eurjhf\/hfs017","article-title":"Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis","volume":"14","author":"Avni","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026011721151587800_ejhf473-bib-0011","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2174\/1871529X11313010004","article-title":"Outcomes of patients with chronic heart failure and iron deficiency treated with intravenous iron: a meta-analysis","volume":"13","author":"Kapoor","year":"2013","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"2026011721151587800_ejhf473-bib-0012","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s13539-013-0109-7","article-title":"Relation of respiratory muscle strength, cachexia and survival in severe chronic heart failure","volume":"4","author":"Habedank","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026011721151587800_ejhf473-bib-0013","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s13539-014-0152-z","article-title":"Skeletal myopathy in patients with chronic heart failure: significance of anabolic\u2013androgenic hormones","volume":"5","author":"Josiak","year":"2014","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026011721151587800_ejhf473-bib-0014","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s13539-014-0155-9","article-title":"Ventricular assist device implantation improves skeletal muscle function, oxidative capacity, and growth hormone\/insulin-like growth factor-1 axis signaling in patients with advanced heart failure","volume":"5","author":"Khawaja","year":"2014","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026011721151587800_ejhf473-bib-0015","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/ejhf.84","article-title":"The additive burden of iron deficiency in the cardiorenal\u2013anaemia axis: scope of a problem and its consequences","volume":"16","author":"Klip","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026011721151587800_ejhf473-bib-0016","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/eurjhf\/hft099","article-title":"Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial","volume":"15","author":"Filippatos","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026011721151587800_ejhf473-bib-0017","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/eurjhf\/hft068","article-title":"The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study","volume":"15","author":"Van Craenenbroeck","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026011721151587800_ejhf473-bib-0018","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jacc.2007.07.029","article-title":"Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency","volume":"50","author":"Toblli","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026011721151587800_ejhf473-bib-0019","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jacc.2007.09.036","article-title":"Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial","volume":"51","author":"Okonko","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026011721151587800_ejhf473-bib-0020","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1016\/j.ijcard.2013.04.181","article-title":"IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia","volume":"168","author":"Beck-da-Silva","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026011721151587800_ejhf473-bib-0021","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cardfail.2009.05.010","article-title":"A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical outcomes","volume":"15","author":"Com\u00edn-Colet","year":"2009","journal-title":"J Card Fail"},{"key":"2026011721151587800_ejhf473-bib-0022","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"2026011721151587800_ejhf473-bib-0023","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"2026011721151587800_ejhf473-bib-0024","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"key":"2026011721151587800_ejhf473-bib-0025","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026011721151587800_ejhf473-bib-0026","article-title":"Patients\u2019 self-assessment of their congestive heart failure, part 2: content, reliability and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire","volume":"198\u2013209","author":"Rector","year":"1987","journal-title":"Heart Fail"},{"key":"2026011721151587800_ejhf473-bib-0027","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"Cochrane Statistical Methods Group. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2026011721151587800_ejhf473-bib-0028","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"2026011721151587800_ejhf473-bib-0029","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"2026011721151587800_ejhf473-bib-0030","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2013"},{"key":"2026011721151587800_ejhf473-bib-0031","first-page":"5","article-title":"Report of a WHO scientific group","volume":"405","author":"Nutritional anaemias","year":"1968","journal-title":"World Health Organ Tech Rep Ser"},{"key":"2026011721151587800_ejhf473-bib-0032","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/eurjhf\/hft050","article-title":"EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026011721151587800_ejhf473-bib-0033","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2012.09.038","article-title":"Rehospitalization for heart failure: problems and perspectives","volume":"61","author":"Gheorghiade","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026011721151587800_ejhf473-bib-0034","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ehf2.12021","article-title":"Improving care for patients with acute heart failure: before, during and after hospitalization","volume":"1","author":"Cowie","year":"2014","journal-title":"ESC Heart Fail"},{"key":"2026011721151587800_ejhf473-bib-0035","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ehf2.12005","article-title":"Heart failure: preventing disease and death worldwide","volume":"1","author":"Ponikowski","year":"2014","journal-title":"ESC Heart Faile"},{"key":"2026011721151587800_ejhf473-bib-0036","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jacc.2008.04.061","article-title":"Anemia and mortality in heart failure patients a systematic review and meta-analysis","volume":"52","author":"Groenveld","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026011721151587800_ejhf473-bib-0037","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10741-011-9283-x","article-title":"Anemia in chronic heart failure: can we treat? What to treat?","volume":"17","author":"von Haehling","year":"2012","journal-title":"Heart Fail Rev"},{"key":"2026011721151587800_ejhf473-bib-0038","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1056\/NEJMoa1214865","article-title":"Treatment of anemia with darbepoetin alfa in systolic heart failure","volume":"368","author":"Swedberg","year":"2013","journal-title":"N Engl J Med"},{"key":"2026011721151587800_ejhf473-bib-0039","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ehf2.12012","article-title":"Clinical trials update from the European Society of Cardiology meeting 2014: PARADIGM-HF, CONFIRM-HF, SIGNIFY, atrial fibrillation, beta-blockers and heart failure, and vagal stimulation in heart failure","volume":"1","author":"Clark","year":"2014","journal-title":"ESC Heart Fail"},{"key":"2026011721151587800_ejhf473-bib-0040","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/ejhf.139","article-title":"High prevalence of iron deficiency in patients with acute decompensated heart failure","volume":"16","author":"Cohen-Solal","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026011721151587800_ejhf473-bib-0041","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1001\/jama.1990.03440100097014","article-title":"The existence of publication bias and risk factors for its occurrence","volume":"263","author":"Dickersin","year":"1990","journal-title":"JAMA"},{"key":"2026011721151587800_ejhf473-bib-0042","first-page":"301","article-title":"Intravenous iron-dextran: therapeutic and experimental possibilities","volume":"100","author":"Ganzoni","year":"1970","journal-title":"Schweiz Med Wochenschr"},{"key":"2026011721151587800_ejhf473-bib-0043","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.473","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/18\/7\/786\/66382733\/eurjhf_18_7_786.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/18\/7\/786\/66382733\/eurjhf_18_7_786.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:15:54Z","timestamp":1768702554000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/18\/7\/786\/8423275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,28]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,1,28]]},"published-print":{"date-parts":[[2016,7,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.473","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,7]]},"published":{"date-parts":[[2016,1,28]]}}}